Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4(16):3977-3989.
Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study. EBioMedicine. 2019..
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer. 2018.
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 positive leukemia and lymphoma in the context of stem cell transplantation. Hum Gene Ther. 2016..
Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. Br J Haematol. 2016.
Bone marrow harvesting of allogeneic donors in an outpatient setting: a single-center experience. Biol Blood Marrow Transplant. 2015.
Effects of physical exercise on survival after allogeneic stem cell transplantation. Int J Cancer. 2015..
In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2014..
Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. Transplantation. 2014.